Search research articles
Contact Us
Filters
Showing results (211-220 of 251) with videos related to
Page
of 26
Sort By:
The Journal of Dermatological Treatment
|
April 7, 2023
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Stefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Psoriasis (Auckland, N.Z.)
|
August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years
Luca Mastorino, Paolo Dapavo, Martina Burlando, et al.
International Journal of Dermatology
|
January 5, 2024
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort
Riccardo Viola, Luca Mastorino, Matteo Megna, et al.
The Journal of Dermatological Treatment
|
September 27, 2019
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
Andrea Chiricozzi, Anna Balato, Curdin Conrad, et al.
Frontiers in Immunology
|
January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Immunology
|
July 31, 2025
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients
Roberta Belli, Anna Dattolo, Francesca Sampogna, et al.
Dermatology and Therapy
|
May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Clinical, Cosmetic and Investigational Dermatology
|
January 13, 2023
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
Luca Stingeni, Giovanna Malara, Andrea Conti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Page
of 26
Search research articles
Search
Showing results (211-220 of 251) with videos related to
Sort By:
Page
of 26
The Journal of Dermatological Treatment
|
April 7, 2023
Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy
Stefano Dastoli, Maria Passante, Francesco Loconsole, et al.
Psoriasis (Auckland, N.Z.)
|
August 12, 2025
Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years
Luca Mastorino, Paolo Dapavo, Martina Burlando, et al.
International Journal of Dermatology
|
January 5, 2024
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort
Riccardo Viola, Luca Mastorino, Matteo Megna, et al.
The Journal of Dermatological Treatment
|
September 27, 2019
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study
Andrea Chiricozzi, Anna Balato, Curdin Conrad, et al.
Frontiers in Immunology
|
January 26, 2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Immunology
|
July 31, 2025
Leptin: a gender and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients
Roberta Belli, Anna Dattolo, Francesca Sampogna, et al.
Dermatology and Therapy
|
May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Clinical, Cosmetic and Investigational Dermatology
|
January 13, 2023
Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
Luca Stingeni, Giovanna Malara, Andrea Conti, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
January 25, 2023
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy
|
January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Page
of 26